Treatment of Coronary Heart Disease Stents: Complete 2026 Doctor’s Guide

By Dr. Sagar Rajkuwar, ENT Specialist, Nashik, Maharashtra, India
🌐 www.entspecialistinnashik.com

Short answer: The modern treatment of coronary heart disease stents is performed through percutaneous coronary intervention (PCI), in which a cardiologist threads a thin catheter through the radial or femoral artery, expands a tiny balloon to open the narrowed coronary artery, and deploys a metal mesh stent — almost always a drug-eluting stent (DES) — to keep it open. Patients then take dual antiplatelet therapy (DAPT) (aspirin + ticagrelor/prasugrel/clopidogrel) for 6–12 months, continue a high-intensity statin, and attend cardiac rehabilitation. If you are reading about the treatment of coronary heart disease stents, this 2026 ENT-authored guide — built on WHO, CDC, NHS, AHA/ACC/SCAI 2021 Revascularisation Guideline, and ESC 2024 — explains every step.

Table of Contents

1. Introduction
2. What Is a Coronary Stent?
3. Types of Coronary Stents in 2026
4. Who Needs a Stent?
5. The PCI Procedure Step-by-Step
6. Dual Antiplatelet Therapy (DAPT)
7. Risks & Complications
8. In-Stent Restenosis & Stent Thrombosis
9. Recovery & Hospital Stay
10. Lifestyle After Stenting
11. PCI vs CABG — When Each Wins
12. Costs & Access in India
13. Follow-Up Schedule
14. Latest 2024–2026 Advances
15. External Video Resource
16. FAQs
17. Conclusion
18. References

1. Introduction

Coronary heart disease (CHD), also called coronary artery disease (CAD), kills around 9 million people a year according to WHO 2024. In most hospitals, the first-line interventional therapy is a stent. The treatment of coronary heart disease stents has evolved dramatically since the first bare-metal stent in 1986 — today’s thin-strut polymer-free drug-eluting stents deliver 1-year major-event rates below 5%.

2. What Is a Coronary Stent?

A coronary stent is a tiny expandable metal mesh tube, usually made from cobalt-chromium or platinum-chromium, that is implanted inside a diseased coronary artery to:

• Open the narrowed segment
• Press plaque against the artery wall
• Maintain long-term luminal patency
• Prevent elastic recoil after balloon angioplasty

Modern stents are coated with an anti-proliferative drug (e.g., sirolimus, everolimus, zotarolimus, biolimus) that is slowly released over weeks to months to prevent re-narrowing — this is the heart of the current treatment of coronary heart disease stents.

3. Types of Coronary Stents in 2026

3.1 Bare-Metal Stents (BMS)

• First-generation; rarely used today
• Still occasionally considered in patients unable to tolerate prolonged DAPT or planned for imminent non-cardiac surgery

3.2 Drug-Eluting Stents (DES)

• Workhorse of modern PCI
• Second- and third-generation DES: everolimus-eluting, zotarolimus-eluting, biolimus-eluting
• Thin struts (60–81 µm), biocompatible polymers or polymer-free surfaces
• Restenosis <5% at 1 year

3.3 Bioresorbable Vascular Scaffolds (BVS)

• Dissolve over 2–3 years
• Early-generation BVS (Absorb) withdrawn in 2017 due to late scaffold thrombosis
• Newer thin-strut magnesium-based scaffolds showing improved safety in 2024 trials

3.4 Drug-Coated Balloons (DCB)

• Deliver antiproliferative drug without implanting a scaffold
• Preferred for small vessels, in-stent restenosis, high bleeding risk

3.5 Bioadaptor Stents (2024–2026)

• Metallic stents designed to unlock after 6 months, restoring vessel pulsatility
• DynamX Bioadaptor — early European approval

4. Who Needs a Stent?

Current guidelines (ESC 2024, ACC/AHA/SCAI 2021) recommend stenting in these groups:

• ST-elevation myocardial infarction (STEMI) — primary PCI within 90 minutes
• High-risk non-ST-elevation MI (NSTEMI) — invasive within 24 hours
• Unstable angina with refractory symptoms
• Stable angina with ≥70% stenosis and symptoms despite optimal medical therapy
• Fractional flow reserve (FFR) ≤0.80 or iFR ≤0.89 in intermediate lesions
• Left-main stenosis if anatomy is suitable

The treatment of coronary heart disease stents is NOT recommended for every narrowing — the ISCHEMIA trial (2020) showed stable CAD patients do equally well with optimised medical therapy for mortality endpoints.

5. The PCI Procedure Step-by-Step

5.1 Pre-procedure

• Informed consent
• Loading dose of aspirin + P2Y12 inhibitor (ticagrelor/prasugrel/clopidogrel)
• Fasting 4–6 hours
• IV cannula, ECG, oxygen saturation monitoring
• Pre-hydration if renal impairment

5.2 Vascular Access

Radial access is now the default (reduces bleeding by 50%); femoral access reserved for complex cases.

5.3 Angiography & Lesion Assessment

• Diagnostic images of all coronary arteries
• FFR / iFR / IVUS / OCT to assess intermediate lesions, stent sizing, plaque burden

5.4 Lesion Preparation

• Pre-dilatation with semi-compliant balloon
• Rotational atherectomy (Rotablator), intravascular lithotripsy, orbital atherectomy, or scoring/cutting balloons in calcified lesions

5.5 Stent Deployment

• Stent positioned across the lesion under fluoroscopy
• Balloon inflated to deploy stent against the artery wall
• Post-dilatation with non-compliant balloon for optimal apposition

5.6 Post-procedure

• Hemostasis at radial site with TR band for 2 hours
• Monitoring in the cath lab recovery
• DAPT continued; statin loading dose

6. Dual Antiplatelet Therapy (DAPT)

DAPT is critical to prevent stent thrombosis — a cornerstone of the treatment of coronary heart disease stents.

• Aspirin 75–100 mg daily + P2Y12 inhibitor
• P2Y12 options: ticagrelor, prasugrel, clopidogrel
• Duration after DES: 6 months for stable CAD; 12 months after ACS (ESC 2023)
• Shortened DAPT (1–3 months) in high bleeding risk per MASTER-DAPT and TWILIGHT
• Extended DAPT beyond 12 months considered in selected high-ischaemic-risk patients

7. Risks & Complications

• Vascular access site: haematoma, pseudoaneurysm, bleeding
• Coronary perforation, dissection
• Peri-procedural MI
• Arrhythmias including ventricular fibrillation
• Contrast-induced nephropathy
• Stroke (0.1–0.2%)
• Allergic reaction to contrast
• In-stent restenosis, stent thrombosis

8. In-Stent Restenosis & Stent Thrombosis

8.1 In-Stent Restenosis (ISR)

• Re-narrowing of a stented segment, usually within 6–12 months
• Rate <5% with modern DES
• Treatment: drug-coated balloons, repeat DES, intracoronary brachytherapy in refractory cases

8.2 Stent Thrombosis

• Acute (<24 h), subacute (1–30 d), late (30 d – 1 y), very late (>1 y)
• Causes: premature DAPT discontinuation, stent malapposition, dissection, hypercoagulability
• Rate 0.5–1%/year; often presents as STEMI
• Prevention: strict DAPT adherence, optimal stent deployment with imaging guidance

9. Recovery & Hospital Stay

• Elective PCI: discharge same day or next morning
• STEMI PCI: 2–5 days in hospital
• Radial site tenderness up to 1 week
• Can resume desk work in 2–3 days; heavy work in 2–4 weeks
• Driving: 1 week after elective PCI; 4 weeks after STEMI (varies by jurisdiction)

10. Lifestyle After Stenting

• Mediterranean / DASH diet
• 150–300 min/week moderate aerobic exercise
• Smoking cessation (highest single-factor benefit)
• BP <130/80 mmHg
• LDL <55 mg/dL on high-intensity statin ± ezetimibe ± PCSK9 inhibitors
• HbA1c <7% if diabetic; SGLT2 inhibitors, GLP-1 receptor agonists
• Weight & waist control
• Sleep 7–9 h; treat OSA
• Daily stress-management practice
• Attend cardiac rehabilitation — reduces 5-year mortality 25%

11. PCI vs CABG — When Each Wins

• PCI preferred: single-vessel disease, acute STEMI, high surgical risk, patient preference
• CABG preferred: left-main disease with high SYNTAX score, 3-vessel disease with diabetes, impaired LV function (FREEDOM, SYNTAX, EXCEL trials)
• Heart Team decision for complex anatomy

12. Costs & Access in India

• Government price cap on DES currently ~INR 30,000; BMS ~INR 7,000
• Total PCI cost in private hospitals INR 1.5–3 lakhs; teaching hospitals less
• Ayushman Bharat PM-JAY covers PCI for eligible families
• Day-care PCI available in several centres

13. Follow-Up Schedule

• Clinic visit at 2 weeks, 1 month, 3 months, 6 months, 12 months, then yearly
• Lipid profile, HbA1c, renal function periodically
• ECG at every visit
• Echocardiography at 6 weeks
• Stress test only if symptoms recur or very high-risk anatomy
• Follow-up angiography not routine

14. Latest 2024–2026 Advances

• Intravascular lithotripsy for heavily calcified lesions (DISRUPT CAD IV)
• Bioadaptor stents (DynamX) — early European approval
• Ultra-thin strut DES — Supraflex Cruz, Orsiro Mission
• Polymer-free DES — BioFreedom
• Short DAPT (1 month) in high bleeding risk — MASTER-DAPT, STOPDAPT-2
• Robotic-assisted PCI expanding
• AI-based angiogram analysis

These innovations continue to refine the treatment of coronary heart disease stents every year.

15. External Video Resource

Watch a visual guide to the treatment of coronary heart disease stents:

YouTube: Coronary Stent PCI Procedure – BHF / AHA / Mayo Clinic

16. FAQs

Q1. How long does a stent last?

Permanent — the metal mesh stays in the artery for life. Only bioresorbable scaffolds dissolve.

Q2. Can a stented artery re-block?

Yes — in-stent restenosis in <5% with modern DES, and stent thrombosis in ~0.5–1%/year.

Q3. Is MRI safe after a stent?

Yes — all modern coronary stents are MRI-conditional, safe at 1.5T and 3T immediately after implantation.

Q4. Can I fly after a stent?

Yes — usually after 2 weeks of stable recovery.

Q5. How long must I take blood thinners?

Minimum 6 months for stable CAD and 12 months after ACS; may be shortened in high bleeding risk per MASTER-DAPT.

Q6. Does a stent cure CAD?

No — it treats a specific blockage. Risk factors must be aggressively controlled to prevent new lesions.

Q7. Can I exercise after a stent?

Yes — gentle walking from day 2; graded return to full aerobic activity through a cardiac rehabilitation programme.

Q8. Is bypass surgery better than stenting?

In left-main disease with high SYNTAX score or 3-vessel disease with diabetes — yes. In most other situations PCI is equivalent or preferred.

17. Conclusion

The modern treatment of coronary heart disease stents is a highly refined, evidence-based procedure that saves millions of lives each year. From primary PCI for STEMI to complex multivessel revascularisation, drug-eluting stents, DAPT and aggressive secondary prevention transform outcomes. But a stent is only one part of the strategy — tight risk-factor control, Mediterranean/DASH diet, exercise, cardiac rehab, and lifelong medication adherence are what truly prevent future events.

18. References

1. Lawton JS, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularisation.
2. Byrne RA, et al. 2023 ESC Guidelines on Acute Coronary Syndromes.
3. Vrints C, et al. 2024 ESC Guidelines on Chronic Coronary Syndromes.
4. Maron DJ, et al. ISCHEMIA trial. NEJM 2020.
5. Valgimigli M, et al. MASTER-DAPT trial. NEJM 2021.
6. Mehran R, et al. TWILIGHT trial. NEJM 2019.
7. WHO Cardiovascular Diseases Fact Sheet 2024.

📞 ENT Consultation & Surgery

Dr. Sagar Rajkuwar (MS-ENT)
Prabha ENT Clinic, Ambad, Nashik
📱 7387590194 | 9892596635
🌐 www.entspecialistinnashik.com

Medical Disclaimer

Medical Disclaimer: This article is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment. Audiogram results should be interpreted by a qualified audiologist or ENT specialist. If you have sudden hearing loss, severe dizziness, ear discharge, or other concerning symptoms, seek medical evaluation promptly. Always consult a qualified cardiologist for stent-related care.